U.S. Markets open in 9 hrs 10 mins

Entheon Biomedical Corp. (ENBI.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.5200-0.0500 (-8.77%)
At close: 3:54PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5700
Open0.5600
Bid0.5200 x N/A
Ask0.5400 x N/A
Day's Range0.5200 - 0.5600
52 Week Range0.2100 - 1.3500
Volume262,778
Avg. Volume427,749
Market Cap21.002M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test
    Newsfile

    Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test

    HaluGen's DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry's first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc. ("HaluGen"), and that it is now available for sale within ...

  • Newsfile

    March Psychedelic Capital Investigates Ethical IP and Financial Instruments

    Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - Microdose Psychedelic Insights ("Microdose"), the leader in B2B psychedelic intelligence, in partnership with The Conscious Fund, the most active VC fund in the psychedelic space, is pleased to present the next edition of Psychedelic Capital. #PsyCap is taking place on March 31 at 1:30pm EST and will feature engaging presentations from Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1), Mind Cure Health Inc ...

  • Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs
    Newsfile

    Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs

    Senior Pharmaceutical & Technology Executive and Current SVP, Chief Information Officer, North America at Kyowa Kirin International plc., Previously of IBM, Schering-Plough, Merck and Gilead Joins Entheon's Advisory Board Vancouver, British Columbia--(Newsfile Corp. - March 3, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce Nancy Maher as Special Advisor of Data Science ...